Re­port: Han­mi’s fail­ure to re­port pa­tient death in ol­mu­tinib study broke South Ko­rea’s med­ical laws

A Ko­re­an pa­tient tak­ing Han­mi’s can­cer drug ol­mu­tinib died from a rare case of Stevens-John­son syn­drome a full 14 months be­fore it was re­port­ed to the coun­try’s health au­thor­i­ties, trig­ger­ing a scram­ble that ul­ti­mate­ly caused its part­ner Boehringer In­gel­heim to abrupt­ly with­draw from their $730 mil­lion part­ner­ship on the drug. And to­day Ko­re­an of­fi­cials de­ter­mined that Han­mi broke two med­ical laws re­lat­ed to mon­i­tor­ing and re­port­ing clin­i­cal tri­als, ac­cord­ing to a re­port from the Ko­re­an Her­ald.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.